MethylGene Q1 net loss widens to C$6.1m
Canadian biopharmaceutical company MethylGene has reported a net loss of C$6.1m or C$0.17 per share for the first quarter ended March 31, 2009 compared to a net loss
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.